GSK launches global consortium with six renowned cancer research centres

GSK launches global consortium with six renowned cancer research centres 


    --  Oncology Clinical and Translational Consortium (OCTC) to
        include centres in US, Canada, France, the Netherlands and
        Spain
    --  Projects to focus on clinical trials including combination
        therapies, as well as translational research

LONDON, UK and PHILADELPHIA, PA, Dec. 5, 2013 /CNW/ - GlaxoSmithKline plc 
[LSE/NYSE: GSK] announced today the formation of the Oncology Clinical and 
Translational Consortium (OCTC), a collaborative scientific research network 
comprised of six internationally renowned comprehensive cancer centres. The 
centres include Gustave Roussy (Villejuif, France), University of Texas MD 
Anderson Cancer Center (Houston, US), Memorial Sloan-Kettering Cancer Center 
(New York, US), Netherlands Cancer Institute (Amsterdam, the Netherlands), 
Princess Margaret Cancer Centre, University Health Network (Toronto, Canada) 
and Vall d'Hebron Institute of Oncology - VHIO (Barcelona, Spain). The 
creation of the consortium underscores GSK's commitment to developing 
innovative patient therapies through rational combination and collaboration 
with external partners to access, cultivate, and stimulate scientific 
innovation.

In forming the consortium, GSK will gain OCTC's expertise in preclinical, 
translational and clinical development of novel anticancer therapeutics 
including kinase inhibitors, epigenome modulating compounds and 
immunotherapies, which are key areas of focus of GSK's cancer research drug 
discovery. The centres will have access to studies with GSK's early stage 
oncology pipeline and opportunities to advance the next generation of novel 
oncology therapeutics. OCTC will foster scientific collaboration among the 
members and GSK.

Consortium members were selected for their international leadership and 
expertise in oncology research. Members will ensure operational alignment, 
collaborating on processes to ensure the highest quality standards for 
collection of biological samples, as well as conduct of biomarker and clinical 
research.

"Each OCTC member institution is recognised internationally as a leader in 
clinical and translational research," said Rafael Amado, Head Oncology R&D at 
GlaxoSmithKline."The consortium together with GSK will design and execute 
research programs in a focused and expeditious way, allowing us to develop new 
diagnostic tools and medicines to better treat cancer patients."

Projects driven through the OCTC will include Phase I/II single agent and 
novel combination trials with GSK's targeted and immune therapies as well as 
translational and preclinical studies.

GSK - one of the world's leading research-based pharmaceutical and healthcare 
companies - is committed to improving the quality of human life by enabling 
people to do more, feel better and live longer. For further information 
please visit www.gsk.com.

GSK Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made 
by GSK, including those made in this announcement, are subject to risks and 
uncertainties that may cause actual results to differ materially from those 
projected. Factors that may affect GSK' s operations are described under Item 
3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012. 

Registered in England & Wales:
No. 3888792 
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS  



SOURCE  GlaxoSmithKline Inc. 
GSK enquiries:  UK Media enquiries:  David Mawdsley +44 (0) 20 8047 5502 
(London) Simon Steel +44 (0) 20 8047 5502 (London) David Daley +44 (0) 20 8047 
5502 (London) Catherine Hartley +44 (0) 20 8047 5502 (London)  US Media 
enquiries:  Melinda Stubbee +1 919 483 2510 (North Carolina) Catalina Loveman 
+1 215 751 4958 (Philadelphia) Anna Padula +1 215 751 4271 (Philadelphia) 
Karen Collins +1 919 483 2527 (North Carolina) Stephen Rea +1 215 751 4394 
(Philadelphia)  Analyst/Investor enquiries:  Ziba Shamsi + 44 (0) 20 8047 3289 
(London) Kirsty Collins (SRI & CG) +44 20 8047 5534 (London) Tom Curry + 1 215 
751 5419 (Philadelphia) Gary Davies + 44 (0) 20 8047 5503 (London) James 
Dodwell + 44 (0) 20 8047 2406 (London) Jeff McLaughlin + 1 215 751 7002 
(Philadelphia) Lucy Singah +44 (0) 20 8047 2248 (London)  Canadian Media 
enquiries  Janet Grdovich 905-819-3363 (Mississauga) 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/December2013/05/c7949.html 
CO: GlaxoSmithKline Inc.
ST: Pennsylvania
NI: HEA  
-0- Dec/05/2013 14:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.